Myriad Genetics, Inc. (MYGN)
| Previous Close | 22.01 |
| Open | 22.44 |
| Bid | 22.36 x 1000 |
| Ask | 22.48 x 1200 |
| Day's Range | 21.99 - 22.88 |
| 52 Week Range | 18.98 - 36.95 |
| Volume | |
| Avg. Volume | 563,350 |
| Market Cap | 1.792B |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | 28.84 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selectio
- GlobeNewswire
Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.
- GlobeNewswire
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio. Compared to st
